The establishment of a novel 'real paclitaxel-sensitive' cell line from a patient suffered from IV stage-ovarian carcinoma.

点击翻译按钮获取中文摘要

Although CBDCA/Paclitaxel(PTX) therapy(CP therapy), or new anti-neoplastic agents such as topotecan and doxil contribute to some improvement on the survival of advanced ovarian carcinomas, it is far from complete control of the disease. However, many of us have been experienced dramatic clinical complete response(CR) cases that resulted to be cured by intensive combination therapy. This is a streak of hope for not only patients, but us as the cancer therapists. A novel cell line, named Opt203 was established from a patient who was suffered from IV stage ovarian carcinoma and successfully treated with 10 courses of CP therapy and two times of interval cytoreductive surgeries, resulted to complete response and maintained the status of no evidence of recurrence(NER) for 20 months. In the study of the characterization of this cell line, we found that Opt203 was very chemo-sensitive against many anti-neoplastic agents, especially paclitaxel(PTX). This result is closely concerned to the clinical course of the original patient. Thus Opt203 line was regarded as "real PTX-sensitive" cell line, and would be a bench mark of PTX sensitive cell line in vitro.